First Light Asset Management LLC Raises Position in Vera Therapeutics, Inc. (NASDAQ:VERA)

First Light Asset Management LLC increased its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 78.8% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,261,246 shares of the company's stock after acquiring an additional 556,012 shares during the period. Vera Therapeutics comprises approximately 5.1% of First Light Asset Management LLC's investment portfolio, making the stock its 6th largest holding. First Light Asset Management LLC owned 1.99% of Vera Therapeutics worth $53,338,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. Huntington National Bank acquired a new stake in shares of Vera Therapeutics in the 4th quarter valued at approximately $26,000. AlphaQuest LLC acquired a new stake in Vera Therapeutics in the fourth quarter valued at $34,000. KBC Group NV grew its position in shares of Vera Therapeutics by 127.2% in the 4th quarter. KBC Group NV now owns 2,477 shares of the company's stock valued at $105,000 after acquiring an additional 1,387 shares during the period. Summit Investment Advisors Inc. increased its stake in shares of Vera Therapeutics by 16.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company's stock worth $196,000 after purchasing an additional 639 shares during the last quarter. Finally, Moors & Cabot Inc. bought a new stake in shares of Vera Therapeutics in the 4th quarter valued at about $220,000. 99.21% of the stock is owned by institutional investors and hedge funds.

Vera Therapeutics Stock Performance

NASDAQ:VERA traded up $0.38 during mid-day trading on Thursday, reaching $23.75. 2,456,439 shares of the company's stock were exchanged, compared to its average volume of 750,124. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. The firm has a market capitalization of $1.51 billion, a PE ratio of -9.10 and a beta of 1.28. Vera Therapeutics, Inc. has a one year low of $18.53 and a one year high of $51.61. The business's fifty day simple moving average is $24.93 and its two-hundred day simple moving average is $35.56.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, beating analysts' consensus estimates of ($0.83) by $0.11. Analysts anticipate that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on VERA. The Goldman Sachs Group started coverage on Vera Therapeutics in a research note on Tuesday, January 28th. They issued a "buy" rating and a $58.00 price objective on the stock. JPMorgan Chase & Co. cut their price target on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a report on Tuesday, March 4th. Guggenheim upped their price objective on shares of Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a report on Thursday, February 27th. Finally, Wolfe Research started coverage on shares of Vera Therapeutics in a research note on Tuesday, February 4th. They set an "outperform" rating and a $49.00 target price for the company. One analyst has rated the stock with a hold rating, six have given a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Vera Therapeutics has an average rating of "Buy" and an average price target of $64.67.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.